NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors ...

NewAmsterdam Pharma Company (NAMS) 2025 Conference June 04, 2025 10:30 AM ET Speaker0 To the Jefferies Healthcare Conference Day one. My name is Dennis, biotech analyst here at Jefferies. I have the great pleasure of having New Amsterdam Pharma here with us, CFO Ian Somaya here. So it's great to see you, Ian, and welcome. Speaker1 Thank you, Dennis. Really appreciate being here. It's an exciting time for the company, and I know we have a lot of great questions we're going get through today. Speaker0 Yeah, y ...

NewAmsterdam Pharma Company (NAMS) FY Conference June 03, 2025 04:20 PM ET Speaker0 Hi, everyone. Thanks for coming. My name is Matt Phipps, biotechnology analyst here at William Blair. I'm glad to announce happy to announce the next company at our Growth Stock Conference. It's New Amsterdam Pharma with Michael Davidson, one of the CEO and and cofounders. It's a, you know, company that's had a lot of success over the past, you know, really couple years, but really demonstrating some great clinical data with ...

NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upco ...

NewAmsterdam Pharma Company N.V. (NAMS) closed the last trading session at $18.37, gaining 21.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $42.71 indicates a 132.5% upside potential.The average comprises seven short-term price targets ranging from a low of $37 to a high of $52, with a standard deviation of $5.28. While the lowest estimate indicates an increase of 101.4% from ...

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.89%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.95, delivering a surprise of -97.92%.Over the last four quarters, the co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact Name of Registrant as Specified in its Charter) | The Netherlands | N/A | | --- | - ...

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results – EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively -- -- Company to host R&D day on June 11 th , 2025 in New York City -- –$808.5 million in cash, cash equivalents and marketable securities at March 31, 2025 – Naarden, the Nethe ...

– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively -- -- Company to host R&D day on June 11th, 2025 in New York City -- –$808.5 million in cash, cash equivalents and marketable securities at March 31, 2025 – NAARDEN, The Netherlands and MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasda ...

– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination with ezetimibe or as monotherapy, reduced LDL-C by 50% and 35%, respectively; in addition, Phase 2 data of obicetrapib in combination with moderate-dose statins showed LDL-C reductions of approximately 70% – – 21% observed reduction in major adverse cardio ...